Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the safety and efficacy of the Hemolung Respiratory Assist System in patients with hypercapnic respiratory failure associated with acute exacerbation of chronic obstructive pulmonary disease (COPD) and a 50% likelihood of failure of noninvasive positive pressure ventilation leading to intubation and mechanical ventilation.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Hemolung Respiratory Assist System | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Hemolung Respiratory Assist System | Device | Patients meeting the inclusion criteria will be placed on the Hemolung Respiratory Assist System. Patients will be weaned from non-invasive ventilation and then the Hemolung. Hemolung support will be provided for up to 7 days. Follow-up exams will be performed every 15 days until hospital discharge or 30 days from completion of Hemolung therapy, whichever is later. |
| Measure | Description | Time Frame |
|---|---|---|
| Frequency of occurrence of serious adverse events while on Hemolung therapy and up to 30 days after cessation of therapy and decannulation. | 30 days | |
| Percentage of patients requiring Mechanical Ventilation | 7 days |
| Measure | Description | Time Frame |
|---|---|---|
| Improvement in patient self assessment of dyspnea using visual analog scale pre- to post-Hemolung therapy. | 7 days | |
| Change in Minute Volume (VE) pre- to end-Hemolung therapy | 7 days | |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| RK Mani, MD | Artemis Health Institute | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Artemis Health Institute | Gurgaon | Haryana | 122001 | India |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 23460154 | Derived | Burki NK, Mani RK, Herth FJF, Schmidt W, Teschler H, Bonin F, Becker H, Randerath WJ, Stieglitz S, Hagmeyer L, Priegnitz C, Pfeifer M, Blaas SH, Putensen C, Theuerkauf N, Quintel M, Moerer O. A novel extracorporeal CO(2) removal system: results of a pilot study of hypercapnic respiratory failure in patients with COPD. Chest. 2013 Mar;143(3):678-686. doi: 10.1378/chest.12-0228. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D012131 | Respiratory Insufficiency |
| D029424 | Pulmonary Disease, Chronic Obstructive |
| ID | Term |
|---|---|
| D012120 | Respiration Disorders |
| D012140 | Respiratory Tract Diseases |
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Number of days in the ICU |
| 30 days |
| Number of days in the hospital | 30 days |
| Number of days alive and off mechanical ventilation for > 48 hours through the end of Day 30 following completion of Hemolung therapy | 30 days |
| Percentage of patients requiring sedation, and hours of sedation | 30 days |
| Number of days on Non-Invasive Positive Pressure Ventilation (NIPPV) | 30 days |
| For patients requiring Mechanical Ventilation, number of days on Mechanical Ventilation | 30 days |
| Duration of weaning time from NIPPV | 7 days |
| Duration of weaning time from Hemolung therapy | 7 days |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |